

Patients	P1	P2	P3	P4	pY
Age	8 months	6 months	1.5 years	2 months	5 years
T Lymphocytes	1,133 (1,400-11,500)	3,498 (1,400-11,500)	2,432 (700-8,800)	2,336 (2200-9,200)	1,650 (850-4,300)
CD4	177 (1,000-7,200)	2,226 (1,000-7,200)	1,952 (400-7,200)	1,440 (1600-6,500)	1,034 (500-2,700)
CD8	942 (200-5,400)	954 (200-5,400)	384 (200-2,800)	672 (300-3,400)	594 (9-49)
% Naive CD4	26 (77-97)	49 (77-97)	ND	50 (73-100)	40 (52-92)
% Naive CD8	4 (31-100)	46 (31-100)	ND	75 (47-100)	86 (19-100)
T cell proliferation					
PHA	Normal	Normal	ND	Normal	Normal
B Lymphocytes					
CD19+	250 (130-6,300)	689 (130-6,300)	512 (160-3,700)	640 (520-2,300)	308 (180-1,300)
%CD19+ CD27+	1 (4.3-8.3)	2.6 (4.3-8.3)	1 (7.5-10.9)	1.3 (2.9-4.5)	1 (11.1-20.4)
Immunoglobulins					
IgG	3.79 (3.35-6.23)	2.9 (2.35-4.37)	2.87 (4.82-8.96)	1.3 (2.95-5.49)	0.57 (5.49-10.19)
IgA	<0.06 (0.27-0.86)	<0.04 (0.20-0.62)	<0.05 (0.33-1.22)	0.21 (0.12-0.38)	<0.06 (0.41-1.41)
IgM	<0.06 (0.48-1.36)	0.67 (0.34-0.95)	<0.05 (0.5-1.53)	<0.1 (0.30-0.85)	<0.04 (0.54-1.53)

Additional File 3. Immunological status of newly described ICF patients. Lymphocyte counts (/ μ l) and serum immunoglobulins (g/l) are indicated. Reference intervals for age are indicated into brackets.